GlassScriptPhysician profile
Neil A Brickman
NPI 1518952894
$5,345.11
in general payments reported to CMS, 2019-2025
37 companies · $830 in 2025
The $830 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $934 · 2020: $193 · 2021: $599 · 2022: $1,189 · 2023: $896 · 2024: $704 · 2025: $830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,355 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.61 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.69 | 2019-2025 | Lo Loestrin Fe, Orilissa, Liletta |
| Sumitomo Pharma America, INC. | $504.72 | 2023-2025 | Myfembree, Gemtesa |
| Myovant Sciences INC. | $397.59 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $390.94 | 2021-2025 | |
| Astellas Pharma US INC | $349.33 | 2023-2025 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $307.02 | 2019-2025 | Paragard T 380a |
| Pfizer INC. | $270.44 | 2019-2025 | |
| Aspira Women'S Health INC | $261.09 | 2021-2025 | Ova1 |
| Hologic Sales and Service, LLC | $213.59 | 2022-2025 | Acessa Provu System, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Amgen INC. | $206.25 | 2019-2023 | Evenity, Prolia |
| Daiichi Sankyo INC. | $191.66 | 2019-2024 | Injectafer |
| Shield Therapeutics INC | $174.34 | 2023-2025 | Accrufer |
| Covidien LP | $158.98 | 2019-2020 | |
| Therapeuticsmd, INC. | $131.13 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $111.79 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $101.52 | 2019-2025 | Slynd |
| Minerva Surgical, INC | $75.72 | 2019-2020 | |
| Millicent US INC | $66.31 | 2025 | Femlyv, Intrarosa, Femring |
| Organon LLC | $61.94 | 2022-2024 | Nexplanon |
| Exact Sciences Corporation | $60.57 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Gynesonics, INC. | $55.43 | 2023-2025 | Sonata Sonography-Guided Transcervical Fibroid Ablation System, Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Channel Medsystems, INC. | $54.87 | 2025 | |
| Avion Pharmaceuticals | $53.43 | 2019-2023 | Balcoltra |
| Sage Therapeutics, LLC | $47.26 | 2025 | Zurzuvae |
| Lupin INC. | $45.03 | 2019-2020 | |
| Ascend Therapeutics US, LLC | $44.39 | 2019-2021 | |
| Agile Therapeutics, INC. | $42.61 | 2022-2023 | Twirla |
| Amag Pharmaceuticals, INC. | $38.54 | 2019-2020 | |
| Allergan, INC. | $35.82 | 2019 | |
| Mylan Pharmaceuticals INC. | $16.51 | 2022 | |
| Meditrina | $14.31 | 2024 | |
| Seqirus USA INC | $13.97 | 2022 | |
| Scynexis, INC. | $13.08 | 2022 | |
| Evofem Biosciences, INC. | $12.41 | 2022 | |
| Duchesnay USA Incorporated | $11.03 | 2019 | |
| Vertical Pharmaceuticals, LLC | $10.80 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neil Brickman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.